Wu., J. et al. Biological Age in Healthy Elderly Predicts Dementia in the Absence of a Brain Marker. Research Square. DEC 11.2020 DOI: https://doi.org/10.21203/rs.3.rs-119310/v1. Preprint
Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.
Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.
Gaudio, E., et al. Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identificaton of Potential Biomarkers for Its Activity. Blood Journal 2020 NOV 6. 136 (S1);17
Jacobs, S. A., et al. Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research 2020 NOV 17 DOI: 10.1158/1078-0432.CCR-20-1831
Hu-Lieskovan, S. et al. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer. 2020; 8(2): e000705.
Ashton, J. et al. Ileal transcriptomic analysis in pediatric Crohn's disease reveals IL17-and NOD-signaling expression signatures in treatment-naïve patients and identifies epithelial cells driving differentially expressed genes. Journal of Crohn's anc Colitis. 2020 NOV 24 https://doi.org/10.1093/ecco-jcc/jjaa236
Desai, J., et al. Potential Mechanisms of Resistance Identified Through Analysis of Multiple biomarkers in Immune-Hot Non-Responders with Non-small Cell Lung Cancer Treated with Tislelizumab. Poster presented at Society for Immunotherapy of Cancer Virtual Congress. 2020 Nov 9-14
Ahmed, S., et al. Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. Br J Haematol. 2020 Nov 29. doic 10.1111/bjh.17246. Online ahead of print
Garg, S. K., et al. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers 2020, 12, 3515; doi:10.3390/cancers1213515
Xu, J., et al. Tumor-Immune Signatures Associated with Response or Resistance to Tislelizumab (ANTI-PD1) in Esophageal Squamous Cell Carcinoma (ESCC) Journal for Immunotherapy of Cancer 2020(8)S3:A1-A959
Lodhi, N., et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 2020(11):44, 4055-4073.
Page last updated April 09, 2021